DOACs use in extreme body-weighted patients: results from the prospective START-register
M Guarascio, L Bertù, MP Donadini… - Internal and Emergency …, 2023 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …
Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry
N Ardeshna, T Feldeisen, X Kong… - Vascular …, 2024 - journals.sagepub.com
Introduction: Direct oral anticoagulants (DOACs) have overtaken warfarin in the treatment of
nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore …
nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore …
[HTML][HTML] Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ED Peterson, V Ashton, YW Chen, B Wu… - American heart …, 2019 - Elsevier
Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real‐world analysis
Y Chugh, K Gupta, HB Krishna… - Pacing and Clinical …, 2023 - Wiley Online Library
Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …
Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence
J Harrington, K Arps, A Wu, AP Carnicelli… - European Heart …, 2022 - academic.oup.com
Introduction Patients with atrial fibrillation (AF) should be prescribed standard-dose (5mg
twice daily) apixaban for stroke prevention unless they meet 2 or more criteria: age≥ 80 …
twice daily) apixaban for stroke prevention unless they meet 2 or more criteria: age≥ 80 …
Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (< 60, 60 to 100, and> 100 kg)
P Domínguez-Erquicia, S Raposeiras-Roubín… - The American Journal of …, 2022 - Elsevier
There is limited knowledge regarding the efficacy and safety of fixed-dose oral
anticoagulants in overweight patients because of the possible increased risk of embolism …
anticoagulants in overweight patients because of the possible increased risk of embolism …
Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes
AM Campbell, E Pae, E Lee, T Jacisin… - Annals of …, 2024 - journals.sagepub.com
Background: Apixaban is commonly used to prevent stroke in older adults with nonvalvular
atrial fibrillation (AF). Although its package insert has specific dose reduction criteria …
atrial fibrillation (AF). Although its package insert has specific dose reduction criteria …
[HTML][HTML] Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI≥ 40
Y Choi, M Kushnir, HH Billett - Blood, 2017 - Elsevier
Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …
Association between Apixaban concentration and clinical outcomes in Asians with atrial fibrillation
SY Lin, CH Kuo, LT Ho, YB Liu, CF Huang… - Circulation …, 2022 - Am Heart Assoc
Apixaban is a direct oral anticoagulant used as a first-line therapy for the prevention of
systemic thromboembolism in patients with atrial fibrillation. In the ARISTOTLE trial …
systemic thromboembolism in patients with atrial fibrillation. In the ARISTOTLE trial …
Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low …
T Patil, S Ali, D Eppes, A Lee, N Jarmukli - Journal of Thrombosis and …, 2024 - Elsevier
Background Limited data exist on the safety and effectiveness of using direct oral
anticoagulants (DOACs) in patients with atrial fibrillation aged 80 years or more with and …
anticoagulants (DOACs) in patients with atrial fibrillation aged 80 years or more with and …